Multigene Panel Testing

Rodrigo Arrangoiz MS, MD, FACS, FSSO

Multi-gene panel testing will identify a pathogenic mutation in 4% to 12% of familial high-risk patients who have tested negative for BRCA1 and BRCA2 mutation.

  • BRCA1 and BRCA2 are still the genes most frequently implicated in hereditary breast cancer predisposition:
    • PALB2, CHEK2, and ATM are the next most common.

Variants of uncertain clinical significance are reported for 20% to 40% of tests.

  • This is likely to improve as data accumulate.

Average cancer risk can be estimated for most of the genes, but this should be adjusted up or down based on family history for management decisions.

Most patients with a pathologic mutation in any of the breast cancer predisposition genes meet the criteria for enhanced surveillance with magnetic resonance imaging.

Risk-reducing surgery is considered for the highest-risk patients.

The results of a genetic test can influence management decisions for the newly diagnosed breast cancer patient.

Breast-Cancer-Genetics-Orange-County-California
Rodrigo Arrangoiz MS, MD, FACS
Cirugía General y Gastrointestinal
Michigan State University
Cirugía Oncológica
Fox Chase Cancer Center
Tumores de Cabeza y Cuello / Cirugía Endocrina
Fox Chase Cancer Center
Tumores de Cabeza y Cuello / Cirugía Endocrina
IFHNOS / Memorial Sloan Kettering Cancer Center
Maestría en Ciencias de Investigación
Drexel University
Certificado por el Colegio Americano de Cirugía
Fellow del Colegio Americano de Cirugía
Fellow de la Sociedad de Cirugia Oncológica
Sociedad Quirúrgica S.C.
Hospital ABC Santa Fé
Av. Carlos Graef Fernández #154

Consultorio 515
Col. Tlaxala, Delg. Cuajimalpa
México, D.F. 05300
Tel: 1103 – 1600 Ext 4515 a la 4517
Fax:1664 – 7164
 
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment